Related Experiment Video
Updated: May 5, 2026

Murine Model of CD40-activation of B cells
Published on: March 6, 2010
Immunologic and hematopoietic effects of CD40 stimulation after syngeneic bone marrow transplantation in mice
S Funakoshi1, D D Taub, M R Anver
1Laboratory of Leukocyte Biology, National Cancer Institute, Frederick Cancer Research and Development Center (NCI-FCRDC), Maryland 21702, USA.
Insights
Stimulating CD40 with its ligand in mice after bone marrow transplantation significantly boosted B cell recovery and function. This treatment also accelerated hematopoietic recovery, improving granulocyte and platelet levels.
Area of Science:
- Immunology
- Hematology
- Transplantation Science
Background:
- CD40 molecule is crucial for B cell differentiation and activation in vitro.
- Limited understanding of CD40 stimulation effects in vivo.
- Investigating CD40 ligand's role in augmenting B cell recovery post-bone marrow transplantation (BMT).
Purpose of the Study:
- To examine the effects of CD40 stimulation in a murine BMT model.
- To assess the potential of soluble recombinant murine CD40 ligand (srmCD40L) in enhancing immune and hematopoietic recovery.
Main Methods:
- Utilized a syngeneic bone marrow transplantation model in mice.
- Administered srmCD40L intraperitoneally twice weekly post-BMT.
- Analyzed B cell progenitors, serum immunoglobulin, splenic mitogen responsiveness, lymphoid organ repopulation, T cell responsiveness, and hematopoietic progenitor cells.
Main Results:
- Increased B cell progenitors (B220+/surface IgM-) in bone marrow.
- Enhanced B cell function, evidenced by increased serum immunoglobulin and LPS responsiveness.
- Accelerated germinal center formation and promoted secondary lymphoid organ repopulation.
- Demonstrated hematopoietic effects, including increased hematopoietic progenitor cells and accelerated granulocyte and platelet recovery.
- In vitro incubation showed direct proliferative effects on hematopoietic progenitor cells.
Conclusions:
- CD40 stimulation via srmCD40L accelerates immune recovery, particularly B cell reconstitution and function.
- srmCD40L treatment also enhances hematopoietic recovery post-BMT, suggesting direct effects on progenitors.
- CD40 ligand stimulation holds promise for improving patient outcomes following bone marrow transplantation.
Abstract:
CD40 is a molecule present on multiple cell types including B lymphocyte lineage cells. CD40 has been shown to play an important role in B cell differentiation and activation in vitro, although little is known concerning the effects of CD40 stimulation in vivo. We therefore examined the effects of CD40 stimulation in mice using a syngeneic bone marrow transplantation (BMT) model in an effort to augment B cell recovery after high dose therapy with hematopoietic reconstitution. After the BMT, mice were treated with or without 2-6 microg of a soluble recombinant murine CD40 ligand (srmCD40L) given intraperitoneally twice a week. A significant increase in B cell progenitors (B220+/ surface IgM-) was observed in the bone marrow of mice receiving the srmCD40L. The treated recipients also demonstrated improved B-cell function with increases in total serum immunoglobulin and increased splenic mitogen responsiveness to LPS being noted. Additionally, srmCD40L treatment promoted secondary lymphoid organ repopulation, accelerating germinal center formation in the lymph nodes. Total B cell numbers in the periphery were not significantly affected even with continuous srmCD40L administration. Lymphocytes obtained from mice treated with the ligand also had increases in T cell mitogen and anti-CD3 mAb responsiveness and acquired the capability to produce IL-4. Surprisingly, treatment with srmCD40L also produced hematopoietic effects in mice, resulting in an increase of BM and splenic hematopoietic progenitor cells in the mice after BMT. Treatment with srmCD40L significantly increased granulocyte and platelet recovery in the peripheral blood. Incubation of BMC with srmCD40L in vitro also resulted in increased progenitor proliferation, demonstrating that the hematopoietic effects of the ligand may be direct. Thus, stimulation of CD40 by its ligand may be beneficial in accelerating both immune and hematopoietic recovery in the setting of bone marrow transplantation.
More Related Videos
14:43Differentiating Functional Roles of Gene Expression from Immune and Non-immune Cells in Mouse Colitis by Bone Marrow Transplantation
Published on: October 1, 2012
08:05Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
Published on: March 17, 2020